MedDeviceGuideMedDeviceGuide
Back

GB PMSR/PSUR Dual Reporting for EU and UK Medical Devices

Structure PMSR and PSUR reports for devices sold in the EU and Great Britain, covering data periods, MHRA format, GB content, FSCA links, and retention.

Ran Chen
Ran Chen
Global MedTech Expert | 10× MedTech Global Access
Published 2026-05-05Last reviewed 2026-05-0518 min read

What This Article Covers / Does Not Cover

This article covers one operational challenge: how to structure your Periodic Safety Update Reports (PSURs) and Post-Market Surveillance Reports (PMSRs) so that a single reporting process satisfies both EU MDR/IVDR requirements and Great Britain's new PMS requirements under SI 2024/1368 (effective 16 June 2025). It provides a side-by-side comparison of both regimes, a unified report template, data-period alignment strategy, GB-specific content sections, and the practical workflow for dual submission.

This article does not cover the fundamentals of PMS planning, PSUR writing methodology, or EU MDR PMS requirements in isolation. For the broader PMS framework, see Post-Market Surveillance Guide. For PSUR writing, see PSUR Periodic Safety Update Report Guide. For UK regulatory requirements, see UK MHRA UKCA Regulation Guide.


Regulatory Background

Great Britain: SI 2024/1368

The UK's Medical Devices (Post-market Surveillance Requirements) (Amendment) (Great Britain) Regulations 2024 (SI 2024 No. 1368) came into force on 16 June 2025. It inserts a new Part 4A into the UK Medical Devices Regulations 2002, establishing PMS obligations for all devices placed on the market or put into service in Great Britain — including CE-marked devices certified under EU MDR/IVDR.

Key Differences: EU MDR vs GB SI 2024/1368

DimensionEU MDR/IVDR (Articles 84–86, Annex III)GB SI 2024/1368 (Part 4A)Practical Implication
Geographic scopeEU/EEA marketGreat Britain (England, Scotland, Wales)Northern Ireland follows EU rules; GB requires separate compliance
PMSR update frequency — Class I / Class A-B IVD"Updated when necessary"Every 3 yearsGB imposes a fixed cadence for low-risk devices
PSUR update frequency — Class IIaEvery 2 yearsEvery 2 yearsAligned
PSUR update frequency — Class IIb, III, AIMD / Class C-D IVDEvery yearEvery yearAligned
Record retentionLifetime of device + period defined in PMS plan15 years (implantable) or 10 years (other) from end of PMS periodGB retention period is explicit; EU is plan-defined
Incident definitionDefined in MDR Art. 2(64)Expanded definition including malfunction, deterioration, incorrect use, inadequate labelingGB is broader
Expected side-effect exclusionExcludes expected and documented side-effectsNo such exclusionGB requires reporting of expected side-effects if they reach incident threshold
Trend reportingStatistically significant increase in frequency/severitySignificant adverse impact on risk analysisGB threshold focuses on risk-analysis impact rather than statistical significance
PSUR bundlingPer device or device categoryPer category/group only if same CER/PER and devices are similarGB bundling criteria are more restrictive
Patient/public engagementNot explicitly requiredPMS plan must consider user experience through patient and public engagementGB adds qualitative data source
MHRA reporting portalEUDAMED (EU)MORE (Manufacturer's On-Line Reporting Environment)Separate submission channels
PSUR submission to ABAvailable to NB upon requestMust be submitted directly to Approved BodyGB is proactive, not reactive
Standardized formatNo mandated templateMHRA published standardized PSUR and PMSR templates (June/September 2025)GB requires specific format

Dual-Report Architecture: Three Options

Option Comparison

OptionDescriptionProsConsRecommended When
A: Unified PSUR with GB AnnexSingle PSUR document structured to satisfy both EU MDR and GB requirements, with a GB-specific annexSingle maintenance effort; consistent data; AB/NB review in one documentMust carefully address all GB-specific requirements; annex may be lengthyDevice sold in both EU and GB with same risk class; manufacturer has unified PMS system
B: Separate PSURs from shared dataEU PSUR and GB PSUR are separate documents drawing from the same PMS databaseClean separation; each optimized for its audienceDouble the document production effort; risk of data inconsistenciesRegulatory strategy requires distinct documents; different NB and AB
C: EU PSUR + GB PMSR (where device is lower risk in one market)EU requires PSUR; GB only requires PMSR (or vice versa)Reduced burden for lower-risk marketMust still verify GB content meets all SI 2024/1368 requirementsDevice has different classification in EU vs. GB

Recommendation

For most manufacturers, Option A (Unified PSUR with GB Annex) is the most efficient. BSI, the largest UK Approved Body, has confirmed that clients should upload a single PSUR that meets both regulations to the BSI Client Portal, using a cover page to identify which regulations, devices, and data periods are covered.


Recommended Reading
EU MDR Post-Market Surveillance Plan: MDCG 2025-10 Practical Guide
RegulatoryEU MDR / IVDR2026-06-09 · 13 min read

Unified PSUR Template (Option A)

Report Structure

SectionEU MDR ContentGB SI 2024/1368 Additional ContentOwner
Cover PageBasic UDI-DI, device name, classification, manufacturer, data collection period, PSUR versionAdd: applicable regulations (state both MDR/IVDR and SI 2024/1368); certificate numbers (NB + AB); whether UKCA, CE, or bothRegulatory Affairs
Executive SummaryBenefit-risk overview, key findings, conclusionsAdd: GB-specific benefit-risk summary; GB market status; summary of GB-specific actions takenMedical / RA
Device DescriptionDevice identification, intended use, classification, accessoriesAdd: GB classification if different from EU; UKCA mark status; UK Responsible Person detailsRA
Volume of Sales / Exposure DataEU/EEA sales data, estimated user populationAdd: GB sales data broken down by GB and NI; worldwide data for comparison per regulation 44ZMCommercial / QA
Serious IncidentsPer EU vigilance requirementsAdd: GB serious incidents using IMDRF AET codes; investigation conclusion codes per MHRA format; MORE portal reference numbersVigilance / QA
Expected Side EffectsExcluded from EU PSURRequired in GB section: report serious incidents related to side effects using IMDRF AET Annex F codes; investigation conclusion codes per MHRA templateVigilance / Medical
Trend ReportingStatistically significant increasesAdd: GB trends assessed against risk analysis impact; pre-determined thresholds; MHRA notification statusVigilance / RA
FSCA SummaryEU FSCAs with dates and scopeAdd: GB-specific FSCAs with MORE portal reference numbers; FSN final dates; regions impacted; linkage to prior PSURsVigilance / RA
PMCF / Clinical DataPMCF findings, literature review, CER updatesAdd: GB-specific clinical data if available; patient/public engagement findings per regulation 44ZF(3)(v)Clinical / RA
Risk Management UpdateUpdated risk-benefit assessment per ISO 14971Add: GB-specific residual risk assessment; impact on UK risk analysisRisk Mgmt
Corrective and Preventive ActionsCAPA summaryAdd: GB-specific CAPAs; MHRA notification recordsQA
Technical Documentation UpdatesChanges to IFU, labeling, designAdd: UKCA labeling changes; UK RP notification recordsRA
ConclusionsOverall benefit-risk conclusionAdd: Separate GB benefit-risk conclusion; statement on continued GB market placementMedical / RA
GB Annex (if applicable)N/ADetailed GB data tables per MHRA standardized format; GB/NI sales breakdown; patient engagement findings; MHRA-specific IMDRF codingRA

Data-Period Alignment Strategy

Challenge

EU PSURs are updated on a rolling basis from the date the device is placed on the EU market. GB PSURs are due within 1 year (Class IIb/III) or 2 years (Class IIa) of the device being placed on the GB market after 16 June 2025 — or within the same period from 16 June 2025 for devices already on the market.

Alignment Decision Tree

Q1: Was the device first placed on the EU market
    before 16 June 2025?
    ├── YES → Q2
    └── NO (launched after 16 June 2025) → Q3

Q2: Was the device already registered with MHRA
    and sold in GB before 16 June 2025?
    ├── YES → GB PSUR data period starts 16 June 2025
    │         (saving provision in SI 2024/1368)
    │         Align EU data period to include this date
    │         if possible
    └── NO → GB PSUR data period starts from GB placement date

Q3: Launch dates in EU and GB are close together?
    ├── YES → Use a single data period covering both markets
    └── NO → Overlapping data periods; extract GB data
              from shared PMS database for GB-specific sections

Data-Period Alignment Table

ScenarioEU Data PeriodGB Data PeriodStrategy
Device on EU market 2022, on GB market 2022Per MDR schedule (e.g., annual)Starts 16 June 2025; first GB PSUR due by 16 June 2026 (Class IIb/III) or 16 June 2027 (Class IIa)Time the next EU PSUR to cover the GB period; include GB data as a subset
Device launched in both markets simultaneously in 2026From launch dateFrom launch dateSingle data period; one unified PSUR
Device on EU market only, GB launch planned 2027From EU launchFrom GB launch (2027)EU PSUR covers EU data; first GB PSUR triggered at GB launch
Device discontinued in EU, still sold in GBLast EU PSUR covers EU dataGB PSUR continues per SI scheduleGB-only PSUR going forward

GB-Specific Content Requirements in Detail

1. Sales/Exposure Data Breakdown

Per MHRA PSUR standardized format (June 2025):

Data ElementEU SectionGB Addition
Cumulative units sold (EU)RequiredN/A
Cumulative units sold (GB)N/ARequired — broken down by GB and NI
Cumulative units sold (Worldwide)OptionalRequired per regulation 44ZM
Estimated user population (GB)N/ARecommended

2. Incident Coding

GB requires IMDRF Adverse Event Terminology (AET) coding:

Code SystemApplicationExample
IMDRF AET Annex DInvestigation conclusion codes"Malfunction of device" → code 1101
IMDRF AET Annex FHealth effects/health impact codes"Infection" → code 0400
MHRA MORE portalIncident reference numbersInclude in FSCA summary table

3. Patient and Public Engagement

SI 2024/1368 regulation 44ZF(3)(v) requires the PMS plan to consider user experience through patient and public engagement "if appropriate." Document:

Evidence SourceHow to Document in PSUR
Patient complaint analysisSummarize themes from GB-specific patient complaints
User feedback surveysInclude GB survey results with response rates
Patient advocacy group engagementDocument any structured engagement sessions
Social media monitoringSummarize GB-specific user feedback from public channels
Healthcare professional feedbackInclude GB HCP feedback from training or support interactions

4. Record Retention

Record TypeEU RetentionGB RetentionPractical Rule
PMS data and resultsLifetime of device (per PMS plan)15 years (implantable) or 10 years (other) from end of PMS periodFollow the longer period; 15 years for implantables, 10 years for others
PSURLifetime of device (per PMS plan)Same as aboveSame
Vigilance reportsPer national requirementsSame as aboveSame
Trend reportsPer PMS planSame as aboveSame

Recommended Reading
Does This US IVD Study Need an IDE, an IND, or Neither?
IVD & DiagnosticsClinical Evidence2026-09-15 · 28 min read

FSCA Linkage Across Both Regimes

FSCA Dual-Notification Workflow

FSCA Identified
      │
      ├── EU Notification
      │     ├── Notify NB via EUDAMED (if applicable)
      │     ├── Submit FSN to national competent authorities
      │     └── Document in EU PSUR
      │
      ├── GB Notification
      │     ├── Submit FSN to MHRA via MORE portal
      │     ├── Use MHRA FSN template
      │     ├── Report to UK Responsible Person
      │     └── Document in GB PSUR section
      │
      └── Cross-Reference
            ├── Link FSCA reference numbers (EU + GB)
            ├── Confirm scope alignment (same devices affected?)
            └── Ensure corrective action timeline meets
                both EU and GB requirements

FSCA Summary Table for Dual PSUR

FSCA Reference (EU)FSCA Reference (GB/MORE)Device(s) AffectedDate Reported (EU)Date Reported (GB)ReasonRegionsStatusLinked to Prior PSUR?
FSCA-2025-001MIR-GB-2025-0045Model X, UDI-DI 123452025-03-152025-03-16Needle guard failureEU + GBClosedNo
FSCA-2025-002MIR-GB-2025-0067Model Y, UDI-DI 678902025-07-012025-07-02Labeling errorEU + GBOpenYes (PSUR 2024)

Practical Workflow: Building the Dual PSUR

Step-by-Step Process

StepActivityOwnerTimelineOutput
1Confirm data period covers both EU and GB requirementsRAT-60 daysAgreed data period
2Extract EU PMS data from PMS databaseQA / VigilanceT-50 daysEU data package
3Extract GB PMS data (GB/NI sales, GB incidents via MORE, GB FSCAs)QA / VigilanceT-50 daysGB data package
4Code GB incidents using IMDRF AET Annex D and FVigilanceT-45 daysCoded GB incident tables
5Document patient/public engagement findings (GB)Clinical / RAT-40 daysGB engagement summary
6Compile unified PSUR using shared templateRAT-30 daysDraft PSUR
7Internal review (medical, QA, legal)Cross-functionalT-20 daysReviewed PSUR
8Upload to NB portal (EU) and AB portal (GB)RAT-10 daysSubmitted PSUR
9Submit to MHRA upon request (GB)RAAs requestedMHRA submission
10File in PMS archive with dual-regulation indexQAT-0Archived PSUR

Common Failure Modes and How to Remediate

Failure ModeRoot CauseHow to Remediate
GB sales data not availableGB sales not tracked separately from EUImplement GB-specific sales tracking in ERP/logistics system; require UK RP to provide market data
GB incidents not coded with IMDRF AETVigilance team used EU coding onlyTrain vigilance staff on IMDRF AET; add MHRA coding requirements to vigilance SOP
Patient/public engagement missing from GB sectionNo GB-specific user feedback collectedAdd GB patient feedback collection to PMS plan; include in complaint analysis SOP
PSUR cover page does not identify both regulationsTemplate only referenced EU MDRUpdate PSUR template to include regulation 44ZM reference and AB certificate numbers
FSCA dates misaligned between EU and GBEU and GB notifications submitted at different timesAlign FSCA notification timelines; submit to MHRA within same 24-hour window as EU
Record retention period too shortCompany used EU plan-defined period which was shorter than GB 10/15 year requirementSet global retention policy to minimum 15 years for implantables, 10 years for others
Trend reporting threshold mismatchEU statistical threshold applied to GB dataDefine separate GB trend threshold based on "significant adverse impact on risk analysis" language
PSUR bundling not permitted under GB rulesEU PSUR bundled by device family; GB requires same CER/PERVerify bundling criteria meet GB requirements; split GB PSUR if necessary
UK Responsible Person not copied on PSUR submissionRA submitted only to ABAdd UK RP to PSUR distribution list; update submission SOP
GB/NI data not broken out from worldwide dataSales data aggregated at global levelWork with commercial ops to provide GB/NI-specific data extraction

Recommended Reading
Swissmedic 2026 PMS Focus Campaign: What Class IIa/IIb/III Manufacturers Must Prepare Now
Post-Market SurveillanceEU MDR / IVDR2026-05-31 · 23 min read

What Goes in the File

Document Index for Dual PMS System

DocumentOwnerLocationCross-Links
PMS Plan (EU)RAEU Technical Documentation, Annex IIIPMS Plan (GB)
PMS Plan (GB)RAGB Technical Documentation, SI 2024/1368PMS Plan (EU)
Unified PSURRANB Portal + AB Portal + MHRA (on request)PMS Plans, CER, Risk File
PMSR (Class I/A-B IVD)RAGB: submitted per SI schedulePMS Plan (GB)
Vigilance SOP (dual regime)QAQMSMORE portal guide, EUDAMED guide
Trend Reporting ProcedureVigilanceQMSRisk Management File
FSCA Register (dual)VigilanceQMSPSUR, CAPA log
IMDRF AET Code ReferenceVigilanceQMS Reference LibraryPSUR coding
Patient Engagement Records (GB)Clinical / RAPMS Data ArchiveGB PSUR section
Record Retention ScheduleQAQMSSI 2024/1368, EU MDR

RACI for Dual PSUR Production

ActivityRACI
Data period alignmentRA ManagerRA DirectorNB, ABPM, QA
EU data extractionVigilance LeadQA ManagerSales, ClinicalRA
GB data extractionVigilance LeadQA ManagerUK RP, SalesRA
IMDRF coding (GB)Vigilance AnalystVigilance LeadRAQA
Patient engagement (GB)Clinical AffairsRA ManagerUK RPQA
Unified PSUR authoringRARA ManagerMedical, LegalPM
Internal reviewMedical / QA / LegalRA ManagerExecutive
Upload to NB portalRARA ManagerPM
Upload to AB portalRARA ManagerUK RPPM
Submit to MHRA (on request)RARA ManagerUK RPLegal
Archive and retentionQAQA ManagerRA

Key Regulatory References

ReferenceRelevance
SI 2024 No. 1368 — The Medical Devices (Post-market Surveillance Requirements) (Amendment) (Great Britain) Regulations 2024Primary GB legislation establishing PMS obligations
MHRA, Medical Devices: Standardised Format for Periodic Safety Update Report (PSUR) (June 2025)GB PSUR template and format requirements
MHRA, Medical Devices: Standardised Format for Post Market Surveillance Report (PMSR) (September 2025)GB PMSR template for Class I / Class A-B IVD devices
EU MDR 2017/745, Articles 84–86, Annex IIIEU PMS, PSUR, and PMSR requirements
EU IVDR 2017/746, Articles 78–80, Annex IIIEU IVD-specific PMS requirements
MHRA, Effective Field Safety Notices: Guidance for ManufacturersFSN format and content expectations for GB
MHRA MORE Portal User Guide (Version 3)Electronic submission of vigilance reports to MHRA
PD CEN ISO/TR 20416:2020PMS guidance referenced in MHRA PMS guidance
IMDRF Adverse Event Terminology (AET)Incident coding required in GB PSUR tables

Pre-Submission Checklist: Dual PSUR Review

  • Data period covers both EU and GB requirements (check GB saving provisions for devices on market before 16 June 2025)

  • Cover page identifies both MDR/IVDR and SI 2024/1368 as applicable regulations

  • NB certificate numbers and AB certificate numbers listed on cover page

  • Sales data broken down into EU, GB, NI, and worldwide per MHRA template

  • GB serious incidents coded with IMDRF AET Annex D and F codes

  • Expected side-effects are included in GB section (no exclusion per GB rules)

  • Trend reporting assessed against GB "significant adverse impact on risk analysis" threshold

  • FSCA table includes both EU and GB/MORE reference numbers

  • Patient/public engagement findings documented in GB section

  • GB retention period (10 or 15 years) confirmed and documented

  • PSUR bundling criteria verified for GB (same CER/PER, similar devices)

  • UK Responsible Person identified and copied on submission

  • PSUR uploaded to both NB portal and AB portal

  • Record ready for MHRA submission upon request

  • IMDRF coding verified against MHRA standardized format examples

  • Internal review completed by medical, QA, and legal